Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Pays The Fees, FDA Should Deliver, Nissen Says Of Missed PDUFA Dates

This article was originally published in The Pink Sheet Daily

Executive Summary

Simplified trials and short-term approvals could speed approval of innovative products, according to the Cleveland Clinic physician.

You may also be interested in...

FDA Commissioner Search: Myths And Reality

Speculation about the next FDA head is well under way, but before it gets out of hand, here are five rules of thumb to keep in mind.

FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins

FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins

Avandia Safety Under The Microscope

Cardiovascular risks identified in a meta-analysis by Steven Nissen prompt immediate announcements of an advisory committee meeting and congressional investigations.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts